Droperidol’s Effect on QT Interval

The Food and Drug Administration (FDA) issued a letter to health care providers on December 4, 2001, concerning the medication, droperidol. The purpose of the warning was to alert health care providers to the possible role of droperidol in the development of torsades de pointes (TdP) in susceptible...

Full description

Saved in:
Bibliographic Details
Published in:Journal of perianesthesia nursing 2006-04, Vol.21 (2), p.82-87
Main Authors: Martinez, Jason B., Moos, Daniel D., Dahlen, Larry L.
Format: Article
Language:English
Subjects:
Adjuvants, Anesthesia - adverse effects
Adverse Drug Reaction Reporting Systems
Antiemetics - adverse effects
Contraindications
Droperidol - adverse effects
Drug Labeling
Drug Monitoring
Humans
Long QT Syndrome - chemically induced
Long QT Syndrome - therapy
Nurse's Role
Postanesthesia Nursing - organization & administration
Risk Factors
Torsades de Pointes - chemically induced
Torsades de Pointes - therapy
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Food and Drug Administration (FDA) issued a letter to health care providers on December 4, 2001, concerning the medication, droperidol. The purpose of the warning was to alert health care providers to the possible role of droperidol in the development of torsades de pointes (TdP) in susceptible patients. The purpose of this article is to explore the role of droperidol in the development of TdP in susceptible patients and current recommendations for the use of droperidol as an antiemetic.
ISSN:1089-9472
1532-8473
DOI:10.1016/j.jopan.2006.02.002